THE GLOBAL CHALLENGE OF TREATING NEURAL RELATED DISORDERS

THE CHALLENGE
Just in Europe the cost of neural related disorders is about 800 billion euros per year with more than 35% of the population afflicted1. The cost of drugs is about 20% of this budget with some of their side effects delivering additional cost. Today 25-35% of the affected population is refractory to medical treatment, moreover, alternative current therapies such as brain stimulation are perceived as too invasive, and their clinical benefit is not predictable enough. One major factor of this limited benefit is because the stimulation therapy is delivered by implanted leads using large metal-based electrodes with low resolution and with big implantable power-hungry systems, driving a 50% patient refusal rate.

THE SOLUTION
Neurotechnologies and bioelectronic implants could be a more precise, patient specific and side-effect free, alternative to classical pharmacotherapy. For that, these systems ideally need to provide relevant biomarker information and to work in closed loop to perfectly adapt to each patient-specific disease and environment. INBRAIN brings high density and high-resolution neuronal interfaces for the Neuro and Bioelectronics field, by developing implants that record and stimulate different nervous system targets depending on the indication, using signal processing to decode and provide a therapeutic response in a personalized way to alleviate neurological-based disorders. We are developing a set of graphene high-count, high-resolution brain interfaces (cortical, subcortical and peripheral) that, powered by an intelligent system platform, have the capability of reading single neural cells at a resolution never seen before, detecting therapy-specific biomarkers and triggering adaptive responses for increased outcomes in personalized neurological therapies

Figure 1: INBRAIN Graphene Brain Interface